Results 21 to 30 of about 13,638 (219)

Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model. [PDF]

, 2020
Prodrug activator gene therapy mediated by murine leukemia virus (MLV)-based retroviral replicating vectors (RRV) was previously shown to be highly effective in killing glioma cells both in culture and in vivo.
Chang, Deching, Chang, Hao-Fang, Chen, Bing-Mao, Chen, Shih-Han, Chen, Thomas C, Collins, Sara, Kasahara, Noriyuki, Lin, Sheng-Che, Lu, Yin-Che, Sun, Jui-Ming, Tai, Chien-Kuo, Wang, Hsin-Ell, Wang, Weijun, Wu, Shu-Fen   +13 more
core   +2 more sources

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs [PDF]

, 2013
Oncolytic viruses are emerging as a potential new way of treating cancers. They are selectively replication-competent viruses that propagate only in actively dividing tumor cells but not in normal cells and, as a result, destroy the tumor cells by ...
Braidwood, L., Conner, J., Graham, A., Graham, S.V.   +3 more
core   +1 more source

Establishing a New Platform to Investigate the Efficacy of Oncolytic Virotherapy in a Human Ex Vivo Peritoneal Carcinomatosis Model

Viruses, 2023
Oncolytic virotherapy constitutes a promising treatment option for many solid cancers, including peritoneal carcinomatosis (PC), which still represents a terminal stage of many types of tumors.
Jana Koch, Julia Beil, Susanne Berchtold, Dina Mönch, Annika Maaß, Irina Smirnow, Andrea Schenk, Mary E. Carter, Linus D. Kloker, Tobias Leibold, Philipp Renner, Marc-H. Dahlke, Ulrich M. Lauer   +12 more
doaj   +1 more source

YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells [PDF]

, 2013
Background: The brain cancer stem cell (CSC) model describes a small subset of glioma cells as being responsible for tumor initiation, conferring therapy resistance and tumor recurrence.
Beier, Dagmar, Girbinger, Vroni, Holm, Per Sonne, Lage, Hermann, Mantwill, Klaus, Mittelbronn, Michel Guy André, Naumann, Ulrike, Schlegel, Jürgen, Seznec, Janina, Surowiak, Pawel   +9 more
core   +1 more source

Atomic Resolution Structure of the Oncolytic Parvovirus LuIII by Electron Microscopy and 3D Image Reconstruction. [PDF]

, 2017
LuIII, a protoparvovirus pathogenic to rodents, replicates in human mitotic cells, making it applicable for use to kill cancer cells. This virus group includes H-1 parvovirus (H-1PV) and minute virus of mice (MVM).
Agbandje-McKenna, Mavis, Baker, Timothy S, Chipman, Paul, Cotmore, Susan, D'Abramo, Anthony, Geilen, Lorena, Halder, Sujata, Janssen, Mandy, Kurian, Justin, Mckenna, Robert, Misseldine, Adam, Pittman, Nikéa, Smith, J Kennon, Tattersall, Peter   +13 more
core   +6 more sources

Autophagy gene activity may act as a key factor for sensitivity of tumor cells to oncolytic vesicular stomatitis virus [PDF]

, 2016
Background: Beclin1 is an important, primary molecule for autophagy. Objectives: It is suggested that the control of the autophagy path increases the sensitivity of tumor cells to VSV.
Arefian, E., Bamdad, T., Nabizadeh, A., Razavi Nikoo, S.H.   +3 more
core   +2 more sources

Myxoma Virus-Encoded Host Range Protein M029: A Multifunctional Antagonist Targeting Multiple Host Antiviral and Innate Immune Pathways

Vaccines, 2020
Myxoma virus (MYXV) is the prototypic member of the Leporipoxvirus genus of the Poxviridae family of viruses. In nature, MYXV is highly restricted to leporids and causes a lethal disease called myxomatosis only in European rabbits (Oryctologous cuniculus)
Masmudur M. Rahman, Grant McFadden
doaj   +1 more source

Advances in the design and development of oncolytic measles viruses. [PDF]

, 2015
A successful oncolytic virus is one that selectively propagates and destroys cancerous tissue without causing excessive damage to the normal surrounding tissue. Oncolytic measles virus (MV) is one such virus that exhibits this characteristic and thus has
Hutzen, Brian, Raffel, Corey, Studebaker, Adam W   +2 more
core   +1 more source

Recombinant Myxoma Virus-Derived Immune Modulator M-T7 Accelerates Cutaneous Wound Healing and Improves Tissue Remodeling

Pharmaceutics, 2020
Complex dermal wounds represent major medical and financial burdens, especially in the context of comorbidities such as diabetes, infection and advanced age.
Jordan R. Yaron, Liqiang Zhang, Qiuyun Guo, Enkidia A. Awo, Michelle Burgin, Lauren N. Schutz, Nathan Zhang, Jacquelyn Kilbourne, Juliane Daggett-Vondras, Kenneth M. Lowe, Alexandra R. Lucas   +10 more
doaj   +1 more source

Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1

Frontiers in Immunology, 2021
Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the past decade. Nevertheless, the majority of patients do not benefit from them.
Victor Cervera-Carrascon, Victor Cervera-Carrascon, Dafne C. A. Quixabeira, Joao M. Santos, Joao M. Santos, Riikka Havunen, Riikka Havunen, Ioanna Milenova, Ioanna Milenova, Jan Verhoeff, Camilla Heiniö, Sadia Zafar, Juan J. Garcia-Vallejo, Victor W. van Beusechem, Tanja D. de Gruijl, Aino Kalervo, Suvi Sorsa, Anna Kanerva, Anna Kanerva, Akseli Hemminki, Akseli Hemminki, Akseli Hemminki   +21 more
doaj   +1 more source